Warberg Asset Management’s BriaCell Therapeutics Warrant expiring 2031 BCTXL Stock Holding History
Bought
Maintained
Sold
Other funds holding BCTXL
SM
Warberg Asset Management's BCTXL Position: Q3 2026 in Review
Warberg Asset Management increased its BriaCell Therapeutics Warrant expiring 2031 (BCTXL) stake by 14% in Q3 2026, buying an estimated $20.7K and bringing the position to 181,612 shares worth $211K. The position accounts for 0.03% of the portfolio, ranked #130.
Warberg Asset Management first reported a position in BCTXL in Q1 2026 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold BCTXL as of Q3 2026.
- Warberg Asset Management held 181,612 shares of BriaCell Therapeutics Warrant expiring 2031 worth $211K as of Q3 2026.
- Warberg Asset Management bought 22,057 BriaCell Therapeutics Warrant expiring 2031 shares in Q3 2026, an estimated $20.7K.
- BriaCell Therapeutics Warrant expiring 2031 made up 0.03% of Warberg Asset Management's portfolio in Q3 2026, its #130 holding.
- Warberg Asset Management first reported a position in BriaCell Therapeutics Warrant expiring 2031 in Q1 2026 and has held it in 3 quarters since.
- 11 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant expiring 2031 as of Q3 2026.
Based on Warberg Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.